Raptor Pharmaceuticals Corp.'s RP103, a delayed-release version of cysteamine, hit its primary endpoint in a Phase III study in nephropathic cystinosis, putting the firm in a good position for filing a new drug application (NDA) in the ultra-orphan indication, though that success was not exactly mirrored in the company's stock.